.png | width = 200 | CAS_number = 85622-93-1 | ATC_prefix = L01 | ATC_suffix = AX03 | ATC_supplemental = | PubChem = 5394 | DrugBank = APRD00557 | chemical_formula = C₆H₆N₆O₂ | molecular_weight = 194.151 g/mol | bioavailability = | protein_bound = 15% | metabolism = Temozolomide is spontaneously hydrolized at physiologic pH to the active species, 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC) and to temozolomide acid metabolite. | elimination_half-life = Temozolomide is rapidly eliminated with a mean elimination half-life of 1.8 hours and exhibits linear kinetics over the therapeutic dosing range. | pregnancy_category = | legal_status = Approved by the FDA on August 11, 1999. Available by prescription only. | routes_of_administration = Oral }}

Background

---

Temozolomide (brand name Temodar®) is an oral alkylating agent used for the treatment of refractory anaplastic astrocytoma -- a type of cancerous brain tumor. A derivative of imidazotetrazine, temozolomide is the prodrug of MTIC (3-methyl-(triazen-1-yl)imidazole-4-carboxamide). Temodar is marketed by Schering Corporation, which also markets other well-known prescription drugs such as Clarinex, Nasonex, Levitra, Cipro, Vytorin, Diprolene, Elocon and Lotrisone.

Indications

• Glioblastoma multiforme: for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment.
• Anaplastic astrocytoma: for the treatment of adult patients with refractory anaplastic atrocytoma (ie. patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine).
• Unlabeled uses: Metastatic melanoma.

Dosage Forms

---

Temozolomide is available in the United States in 5mg, 20mg, 100mg, & 250mg capsules.

External links

---

• Official Temodar Website
• Schering-Plough Website

Chemotherapeutic_agents